Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects
Information source: Endo Pharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Pain
Intervention: Oxymorphone IR - Opioid (Drug)
Phase: Phase 3
Status: Terminated
Sponsored by: Endo Pharmaceuticals Official(s) and/or principal investigator(s):
Sr. Director CR&D, Study Director, Affiliation: Endo Pharmaceuticals
Summary
Patients will convert from current opioid to Oxymorphone ER and undergo titration. During
the Titration Period, subjects will receive daily oxymorphone Extended Release tablets(s)
every 12 hours. Dosing adjustments will be based on the review of the subject's pain
scores. Oxymorphone IR 5 mg will be provided to be used as supplemental "breakthrough" pain
medication (as needed). Titration Period will end when the fixed dose of study medication
is tolerated and the subject achieves adequate analgesia. Subjects will then proceed to the
open-label 3-month maintenance period on the fixed dose of study medication established
during the Titration Period.
Clinical Details
Official title: An Open-Label Safety and Tolerability Study of Immediate-Release and Extended-Release Oxymorphone in Opioid-Tolerant Pediatric Subjects With Chronic Pain.
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Change in pain intensity from baseline to last assessment using the FPS-R.
Secondary outcome: Assessment of AEs, vital signs, and physical examinations.
Detailed description:
An Open-Label Safety and Tolerability Study of Immediate-Release and Extended-Release
Oxymorphone in Opioid-Tolerant Pediatric Subjects With Chronic Pain.
Eligibility
Minimum age: 6 Years.
Maximum age: 17 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Have chronic cancer or non-cancer pain, currently requiring treatment of pain with a
strong opioid for at least 5 days (3 of 5 days at a dose greater than or equal to 45
mg/daily (qd) oral morphine equivalent)
- Weigh at least 50 kg
- Expected to continue to require a strong opioid for pain relief for at least 4 weeks
and up to 4 months.
Exclusion Criteria:
- Have a life expectancy <4 weeks
- Plan to undergo a surgical procedure within 3 days of study entry or during the
Titration Period
- Have dysphagia or difficulty swallowing whole tablets
- Have a previous exposure to oxymorphone
- Have an ileostomy
Locations and Contacts
Arkansas Childrens's Hospital-Division of Pediatric Anestesia and Pain Medicine, Little Rock, Arkansas 72202, United States
Stanford University School of Medicine, Stanford, California 94305, United States
The Children's Hospital, Aurora, Colorado 80045, United States
Connecticut Children's Medical Center, Hartford, Connecticut 06106, United States
Children's National Medical Center, Washington, District of Columbia 20010, United States
Florida Institute of Medical Research, Jacksonville, Florida 32257, United States
Tukoi Clinical Research, Miami, Florida 34104, United States
St. Joseph's Children's Hospital of Tampa, Tampa, Florida 33618, United States
Taylor Research, LLC, Marietta, Georgia 30060, United States
Rehabilitation Associates of Indiana, Indianapolis, Indiana 46250, United States
University of Louisville Reserach Foundation, Inc., Louisville, Kentucky 40202, United States
The Center for Clinical Research, Winston-Salem, North Carolina 27103, United States
Hershey Medical Center, Hershey, Pennsylvania 17112, United States
Additional Information
Starting date: October 2008
Last updated: June 10, 2015
|
